AI Summary & Key Takeaways
AI InsightThere were no statistically significant differences with respect to loss of goblet cellsand squamous cell metaplasia among the studied groups (p>0.05).Conclusion: Methotrexate may be an alternative or adjuvant therapeutic agent in allergic rhinitis.
📌 3 Key Takeaways
Abstract
Objectives: This study aims to investigate the therapeutic effect of low-dose topical administration of methotrexate (MTX) in atoluene diisocyanate (TDI)-induced allergic rhinitis rat model.Materials and Methods: The experiments were performed on 18 healthy male Wistar albino rats weighing between 250-270 g. Ratswere divided into four study groups: control group (n=5), sham group (n=3), steroid group (n=5), and MTX group (n=5). After the drugswere administered, multiple biopsies were taken bilaterally from the nasal mucosal areas and evaluated histologically for fibrosis, lossof cilia and goblet cells, edema, squamous cell metaplasia, and vascular proliferation.Results: Fibrosis, loss of cilia cells, edema, and vascular proliferation were significantly lower in both MTX and steroid groups thanin the control group (p0.05). There were no statistically significant differences with respect to loss of goblet cellsand squamous cell metaplasia among the studied groups (p>0.05).Conclusion: Methotrexate may be an alternative or adjuvant therapeutic agent in allergic rhinitis.